# Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

> **NCT05022563** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 55759 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Parenteral anticoagulant
- **DRUG:** Warfarin
- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban
- **DRUG:** Dabigatran
- **DRUG:** Edoxaban

## Key facts

- **NCT ID:** NCT05022563
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-31
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 55759 (ACTUAL)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022563, "Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05022563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*